Clinical trials and evidence
Clinical trials and real-world evidence support evidence-based medicine in healthcare, playing a pivotal role in validating and advancing medical treatments and interventions. Clinical trials assess the efficacy and safety of new drugs and therapies, with real-world evidence providing data to inform clinical and regulatory decisions based on empirical data.
Top Stories
-
Podcast
18 Sep 2024
Exploring chronic disease management trends, strategies
Chronic disease management and prevention strategies are of increasing importance as chronic conditions increase in prevalence. Continue Reading
-
News
26 Aug 2024
Long COVID effects in adolescents, young children vary
NIH-funded research through the RECOVER initiative revealed that long COVID symptoms among pediatric patients varied from sleepiness to headaches, underscoring vaccine importance. Continue Reading
-
Feature
27 Apr 2022
Exploring Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs)
Selective serotonin reuptake inhibitors are the most commonly prescribed medications for treating major depressive disorder, anxiety disorders, and other psychological conditions. Continue Reading
-
News
25 Apr 2022
FDA Grants Priority Review for Non-Small Cell Lung Cancer Drug
AstraZeneca and Daiichi Sankyo's non-small cell lung cancer drug, Enhertu, elicited an objective response rate of 54.9% and a partial response rate of 53.8%. Continue Reading
-
News
21 Apr 2022
Sanofi's BTK Inhibitor Effective in Immune Thrombocytopenia Patients
In the Phase 1/2 clinical trial, 24 of the 60 pre-treated immune thrombocytopenia patients enrolled in the study achieved the primary endpoint with any dosing regimen. Continue Reading
-
News
21 Apr 2022
FDA Lifts Hold on Gilead’s MDS, AML Clinical Trials
FDA lifts the partial hold placed on clinical trials evaluating Gilead’s magrolimab combined with azacitidine in myelodysplatic syndrome (MDS) and acute myeloid leukemia (AML) patients. Continue Reading
-
Feature
20 Apr 2022
Major Milestones in Medicine, Drug Development in Recorded History
The past few centuries have witnessed several revolutionary milestones in modern medicine and drug development that have drastically improved human health. Continue Reading
-
News
19 Apr 2022
Moderna Doses Participants in Study of Two Influenza mRNA Vaccines
The trial will evaluate the safety, reactogenicity, and immunogenicity of a single dose of Moderna's influenza mRNA vaccine candidates in 560 adults 18 years of age and older. Continue Reading
-
News
14 Apr 2022
Eli Lilly's Retevmo Helps Non-Small Cell Lung Cancer Patients
In the Phase 1/2 trial, the objective response rate was 61.1% in non-small cell lung cancer patients previously treated with platinum chemotherapy and 84.1% in treatment-naïve patients. Continue Reading
-
News
14 Apr 2022
Pfizer to Acquire BioPharma Company to Develop RSV Therapeutics
Pfizer will acquire ReViral and its portfolio of promising RSV therapeutics, including sisunatovir, designed to block the fusion of the RSV virus to the host cell. Continue Reading
-
News
13 Apr 2022
Michigan Blue Launches Pharmacogenomics Precision Medicine Program
Blue Care Network recently announced the launch of Michigan’s first end-to-end pharmacogenomics precision medicine program, Blue Cross Personalized Medicine. Continue Reading
-
News
07 Apr 2022
New Toolkit Supports Digital Endpoints in Drug Development
DiMe, Biogen, Eli Lilly, Pfizer, and other top pharma companies launched a toolkit to ensure that organizations develop digital endpoint evidence in an acceptable way during drug development. Continue Reading
-
News
06 Apr 2022
Roche’s Small Cell Lung Cancer Antibody Fails in Phase 3 Trial
In the Phase 3 clinical trial, small cell lung cancer patients who received the antibody did not achieve overall survival and are unlikely to reach statistical significance at the final analysis. Continue Reading
-
News
05 Apr 2022
AstraZeneca to Share New Data on Oncology Treatment Landscape
AstraZeneca will share new potential oncology treatments, which span its immuno-oncology (IO), DNA damage response (DDR), and antibody–drug conjugate (ADC) scientific platforms. Continue Reading
-
News
04 Apr 2022
Merck’s CMV Drug Lowers Reactivation by 88% After Cell Transplant
Merck’s CMV drug, Prevymis, lowered the chance for clinically significant CMV infection by 91% 100 days after allogeneic hematopoietic cell transplant (alloHCT). Continue Reading
-
News
04 Apr 2022
Pfizer’s S1P Modulator Drug Helps Ulcerative Colitis Patients
Ulcerative colitis patients achieved statistically significant improvements in the co-primary endpoints of clinical remission at weeks 12 and 52 compared to placebo in a Phase 3 trial. Continue Reading
-
News
29 Mar 2022
Pfizer’s Ulcerative Colitis Drug Helps Patients in Phase 3 Study
The global Phase 3 study found that the ulcerative colitis treatment improved clinical remission at week 12 and all key secondary endpoints. Continue Reading
-
News
29 Mar 2022
Vivalink's Biometrics Data Platform Monitors Oncology Patients
A clinical trial of 80 oncology patients undergoing outpatient intermediate-risk chemotherapy regimens will leverage Vivalink's biometrics data platform to detect neutropenic fever events. Continue Reading
-
News
28 Mar 2022
Moderna Will Expand mRNA Vaccine Pipeline Through 2 New Programs
Moderna will launch a respiratory combination vaccine program to target three viruses causing respiratory disease in adults and a program to develop an mRNA vaccine candidate for HCoVs. Continue Reading
-
News
24 Mar 2022
Thermo Fisher to Invest $97M to Expand Drug Development Efforts
Over the next three years, Thermo Fisher will add nearly 150,000 square feet and over 500 new employees to its Richmond, Virginia laboratory to further drug development. Continue Reading
-
News
24 Mar 2022
Pfizer Submits for EUA of Additional COVID-19 Vaccine Booster
In other COVID news, Roche provides molecular testing solutions to identify SARS-CoV-2 variants and Moderna will provide Switzerland with an additional 7 million COVID-19 vaccine doses. Continue Reading
-
News
23 Mar 2022
Keytruda Boosts Survival Rate for Non-Small Cell Lung Cancer
The randomized Phase 3 trial found that Merck’s Keytruda decreased the risk of disease recurrence or death by 24% compared to placebo in non-small cell lung cancer patients. Continue Reading
-
Feature
22 Mar 2022
How Regulation Stymies Medical Research of Controlled Substances
Barriers to medical research constructed by federally controlled substance scheduling and classification stifle the development of safe and effective products aimed to improve overall human health. Continue Reading
-
News
22 Mar 2022
AstraZeneca Launches R&D Challenge to Advance Drug Discovery
MD students, PhD students, and postdoctoral researchers worldwide can propose their innovative ideas and help boost drug discovery across AstraZeneca’s core disease areas. Continue Reading
-
News
21 Mar 2022
Boehringer Ingelheim Halts Chronic Kidney Disease Trial
Boehringer Ingelheim will stop the Phase 3 EMPA-KIDNEY trial after clear positive efficacy of empagliflozin in adults with chronic kidney disease. Continue Reading
-
News
21 Mar 2022
Moderna Doses First Patient in HIV mRNA Vaccine Clinical Trial
The primary hypothesis is that the HIV-uninfected individuals will tolerate the HIV envelope trimer mRNA vaccines and elicit autologous neutralizing antibodies. Continue Reading
-
News
17 Mar 2022
Civica to Manufacture Lower-Priced Insulin for Diabetes Patients
The availability of three affordable insulins will benefit diabetes patients forced to choose between life-sustaining medicines and living expenses. Continue Reading
-
News
17 Mar 2022
Pfizer’s C. Difficile Vaccine Misses Primary Endpoint in Trial
Pfizer’s C. difficile vaccine did not meet its primary endpoint in a Phase 3 trial after COVID-19 forced the company to accrue fewer cases of CDI over a longer period than initially intended. Continue Reading
-
News
16 Mar 2022
Novo Nordisk Expands Collaboration in Oral Drug Delivery Tech
The collaboration in oral drug delivery technologies now extends through 2026, expanding the scope to include the integration of bioelectronics, biosensors, and delivery devices. Continue Reading
-
News
14 Mar 2022
Gilead’s Trodelvy Helps HR/HER2 Metastatic Breast Cancer Patients
Researchers targeted a 30% reduction in the risk of disease progression or death in breast cancer patients in the Phase 3 TROPiCS clinical trial. Continue Reading
-
Feature
09 Mar 2022
Understanding the Value, Complexity of Clinical Trials in the US
Clinical trials in the US study new drug developments and evaluate the effects in humans. Continue Reading
-
News
07 Mar 2022
AstraZeneca, Alexion, Neurimmune to Develop Rare Disease Antibody
The monoclonal antibody, NI006, is currently Phase 1b development to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a generally underdiagnosed rare disease. Continue Reading
-
Feature
04 Mar 2022
Understanding US Food and Drug Administration (FDA) Approval Processes
The FDA approvals process is complex and time-consuming, taking an average of 12 and 7 years for drugs and devices, respectively. Continue Reading
-
News
02 Mar 2022
CHMP Recommends Pfizer, Biohaven’s Generic Drug for Migraine Attacks
In all studies, 75 milligrams of generic drug rimegepant was safe and well-tolerated with rates of adverse events similar to placebo. Continue Reading
-
News
01 Mar 2022
ACIP Recommends Pfizer’s TBE Vaccine For Individuals Most At Risk
ACIP recommends Pfizer’s TBE vaccine for individuals one year and older who travel or move to TBE endemic areas or have extensive exposure to ticks. Continue Reading
-
News
01 Mar 2022
Moderna, Thermo Fisher to Boost mRNA Vaccine Manufacturing
Thermo Fisher will provide capacity for a range of aseptic fill/finish services for Moderna’s COVID-19 vaccine and mRNA vaccine pipeline to increase capacity in the US. Continue Reading
-
News
28 Feb 2022
Moderna Expands mRNA Vaccine Pipeline for HSV, VZV, Cancer
Moderna’s expansion includes three new development programs for an HSV-2 vaccine, a VZV vaccine, and a checkpoint mRNA vaccine for cancer. Continue Reading
-
News
23 Feb 2022
Gilead’s HIV-1 Drug Achieves High Rates of Virologic Suppression
Gilead’s HIV-1 capsid inhibitor achieved high rates of virologic suppression and clinically meaningful increases in CD4 counts in a Phase 2/3 trial of individuals with HIV. Continue Reading
-
News
23 Feb 2022
Moderna, ROVI Expand Collaboration to Boost mRNA Vaccines
The companies will increase mRNA manufacturing across ROVI’s facilities in Spain and utilize ROVI’s platform to service future Moderna mRNA vaccine candidates. Continue Reading
-
News
22 Feb 2022
Merck’s Keytruda, Chemotherapy Helps High-Risk Breast Cancer
The estimated three-year event-free survival rates for patients with high-risk breast cancer were 84.5 percent in the Keytruda group and 76.8 percent in the chemotherapy-placebo group. Continue Reading
-
News
21 Feb 2022
AstraZeneca’s Chemotherapy Treatment Improves Prostate Cancer
AstraZeneca’s combination chemotherapy treatment reduced the risk of disease progression or death by a third in metastatic castration-resistant prostate cancer (mCRPC) patients. Continue Reading
-
News
16 Feb 2022
Merck KGaA to Assess Quris AI Platform for Clinical Prediction
Merck KGaA will assess the company’s AI platform with the initial investment focusing on identifying potential liver toxicity risks for drug candidates. Continue Reading
-
News
16 Feb 2022
Biogen, Xbrane Develop Preclinical Monoclonal Antibody, Biosimilar
The preclinical monoclonal antibody and biosimilar candidate has the potential to add another option for patients living with rheumatoid arthritis and other indications Continue Reading
-
News
14 Feb 2022
Abbott Implants Dual-Chamber Leadless Pacemaker in Clinical Trial
The clinical trial will evaluate the safety and efficacy of Abbott's Aveir DR leadless pacemaker in patients across the US, Canada, and Europe indicated for dual-chamber bradycardia pacing. Continue Reading
-
News
14 Feb 2022
Biogen to Develop, Commercialize Genentech’s Bispecific Antibody
Genentech’s bispecific antibody is currently in development to treat individuals with B-cell non-Hodgkin’s lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). Continue Reading
-
News
10 Feb 2022
Pfizer Confirms Positive Date of Lyme Disease Vaccine Candidate
Positive results from the Phase 2 clinical trial of Pfizer’s Lyme disease vaccine candidate support using a three-dose primary series in the planned Phase 3 trial. Continue Reading
-
News
08 Feb 2022
Personalized Immunotherapy Could Treat Metastatic Breast Cancer
In a Phase 2 study, 67% of women generated an immune reaction against their cancer, suggesting that personalized immunotherapy could treat metastatic breast cancer. Continue Reading
-
News
07 Feb 2022
CVS Health, Medable Expand Clinical Trial Access, Engagement
The collaboration will combine Medable’s software platform with CVS Health’s community reach and experienced MinuteClinic providers to boost clinical trial access and engagement. Continue Reading
-
News
01 Feb 2022
Moderna, IAVI Dose First Patients in Trial of HIV Vaccine Antigens
The Phase 1 trial will test whether HIV vaccine antigens can induce specific classes of B-cell responses and guide early maturation toward neutralizing antibody development. Continue Reading
-
News
31 Jan 2022
Opioid Use Disorder Medicine Lacking for Pregnant Women in US Jails
The study found that 39.7% of jails did not allow continuation of opioid use disorder medicine during pregnancy and only 31.9% permitted initiation of OUD medication during pregnancy. Continue Reading
-
News
26 Jan 2022
AstraZeneca Combination Treatment Helps Advanced Biliary Tract Cancer
In a Phase 3 clinical trial, biliary tract cancer patients who received the combination treatment experienced a 20% reduction in the risk of death versus chemotherapy alone. Continue Reading
-
News
26 Jan 2022
NIH Launches Competition to Boost Neuromodulation Therapies
NIH will bridge the gap between early-stage research and clinical use for neuromodulation therapies targeting multiple functions involving the body's internal organs. Continue Reading
-
News
25 Jan 2022
The Center for Breakthrough Medicines, UPenn Boost Gene Therapies
The Center for Breakthrough Medicines and the UPenn Gene Therapy Program partner to advance gene therapies and move therapeutics safely and rapidly from concept to clinic. Continue Reading
-
News
24 Jan 2022
Moderna, Carisma Partner to Develop In Vivo Cancer Therapies
Moderna taps Carisma’s engineered macrophage technology to generate and develop in vivo cancer therapies to expand its oncology pipeline. Continue Reading
-
News
20 Jan 2022
AstraZeneca to Discover Precision Medicines for Undruggable Targets
AstraZeneca and Scorpion Therapeutics will develop precision medicines for undruggable targets using transcription factors to control gene expression and regulate cell processes. Continue Reading
-
News
20 Jan 2022
Pfizer, Beam Focus on Precision Medicine for Rare Diseases
The four-year research collaboration will leverage in vivo technologies to generate a new precision medicine class that targets rare diseases. Continue Reading
-
News
19 Jan 2022
Bristol Myers, Century to Develop Allogeneic Cell Therapies
The first two programs under the partnership will focus on allogeneic cell therapies for acute myeloid leukemia and multiple myeloma. Continue Reading
-
News
18 Jan 2022
Johnson & Johnson Taps Microsoft to Expand Digital Surgery Ecosystem
Microsoft will help Johnson & Johnson advance its digital surgery ecosystem to advance skills, improve workflow, and boost decision-making to increase the overall patient experience. Continue Reading
-
News
17 Jan 2022
Pfizer, Biohaven to Commercialize Small Molecule Migraine Drugs
The companies will bring the small molecule treatment options to the millions of people across the globe suffering from migraines. Continue Reading
-
News
13 Jan 2022
Pfizer Gains Access to LPN Tech For mRNA Vaccines, Therapeutics
Pfizer taps Acuitas Therapeutics for its lipid nanoparticle (LNP) technology to deliver potential new breakthrough mRNA vaccines and therapeutics. Continue Reading
-
News
13 Jan 2022
Sanofi, Exscientia to Research, Develop Small Molecule Drugs
Sanofi and Exscientia will identify and select target small molecule drug candidates for various chronic diseases and diseases with unmet medical needs. Continue Reading
-
News
12 Jan 2022
Real-World Evidence Confirms J&J COVID-19 Vaccine Protection
In the real-world evidence study, Johnson & Johnson’s single-shot COVID-19 vaccine was 81% effective against hospitalizations and 74% effective against breakthrough infections. Continue Reading
-
News
12 Jan 2022
Eli Lilly Enters Partnership for Nucleic Acid Delivery Technology
Eli Lilly & Company gains exclusive rights to Entos Pharmaceuticals’ nucleic acid delivery technology to research and develop proteo-lipid vehicles. Continue Reading
-
News
11 Jan 2022
Moderna Doses First Participant in Study of EBV mRNA Vaccine
The Phase 1 study will enroll nearly 270 participants 18 to 30 years of age to assess the safety and tolerability of Moderna’s Epstein-Barr Virus (EBV) mRNA vaccine candidate. Continue Reading
-
News
11 Jan 2022
Convalescent Plasma Reduces COVID-19 Hospitalizations Nearly 50%
A nationwide trial found that 2.9% of patients who received convalescent plasma required hospitalization within 28 days of their infusion, compared to 6.3% who received placebo. Continue Reading
-
News
10 Jan 2022
Novartis, Alnylam Leverage siRNA Technology for Liver Disease
The companies will leverage siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research. Continue Reading
-
News
04 Jan 2022
South African Study Shows J&J’s COVID-19 Vaccine 85% Effective
J&J’s COVID-19 vaccine effectiveness increased over time from 63% at 0-13 days to 84% at 14-27 days, and 85% at one to two months post-boost. Continue Reading
-
News
30 Dec 2021
FDA Grants Emergency Authorization to Roche’s At-Home COVID-19 Test
The at-home COVID-19 test can produce accurate results in as little as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron. Continue Reading
-
News
29 Dec 2021
Hackensack Meridian Health Supports Immuno-Oncology Platform
Hackensack Meridian Health supports the development of Alloplex Biotherapeutics’ immuno-oncology platform, which brings a highly-differentiated approach to cell therapy development. Continue Reading
-
News
22 Dec 2021
Bristol Myers Squibb Partners for Bispecific T-Cell Candidate
Bristol Myers Squibb enters into an agreement with Immatics for its most advanced bispecific T-cell candidate, IMA401. Continue Reading
-
News
21 Dec 2021
Moderna’s COVID-19 Vaccine Booster Protects Against Omicron
Preliminary trial data shows that Moderna’s COVID-19 vaccine booster neutralized antibody levels against Omicron nearly 37-fold compared to pre-boost levels. Continue Reading
-
News
21 Dec 2021
Kite’s Yescarta Helps High-Risk Large B-Cell Lymphoma Patients
89% of patients receiving Yescarta achieved a complete response, including 78 percent with a complete response at the median follow-up of 15.9 months. Continue Reading
-
News
20 Dec 2021
J&J’s CAR T-Cell Therapy Effective in Multiple Myeloma Patients
About 83% of multiple myeloma patients who received J&J’s CAR T-cell therapy achieved complete response at the 22-month follow-up, an increase from 80% at the 18-month follow-up. Continue Reading
-
News
16 Dec 2021
Roche Launches Platform to Advance Next-Generation Sequencing
The AVENIO Edge System is a scalable, cost-efficient solution for next-generation sequencing laboratories seeking high performance and agility. Continue Reading
-
News
16 Dec 2021
J&J’s COVID-19 Vaccine Booster Increased Antibody, T-Cell Responses
The T-cell response data suggest differences between immune responses following homologous boosting of J&J’s COVID-19 vaccine. Continue Reading
-
News
15 Dec 2021
AstraZeneca Enters Agreement for Transthyretin Amyloidosis Medicine
Eplontersen is currently in Phase 3 development to treat transthyretin amyloidosis, a systemic, progressive, and fatal condition. Continue Reading
-
News
13 Dec 2021
Roche, TIB Molbiol Develop More COVID-19 Tests To Identify Variant
The three COVID-19 test kits will allow differentiation between unique mutations present in the Omicron variant compared to other variants. Continue Reading
-
News
10 Dec 2021
3 Doses of Pfizer’s COVID-19 Vaccine Neutralizes Omicron Variant
In other COVID news, Medicago’s COVID-19 vaccine was 71% effective in a Phase 3 trial and Europe extends Roche’s Actemra authorization to include the treatment of COVID-19. Continue Reading
-
News
09 Dec 2021
GSK, University of Oxford to Uncover Mechanisms of Disease
The Oxford-GSK Institutes of Molecular and Computational Medicine will build on insights from human genetics and leverage advanced technology to unravel mechanisms of disease. Continue Reading
-
News
09 Dec 2021
Thermo Fisher Introduces Protein To Advance CRISPR Gene Editing
The protein eliminates off-target effects compared to wild-type Cas9 in several cell types for more precise CRISPR gene editing. Continue Reading
-
News
08 Dec 2021
GSK Initiative Addresses Key Challenges In Multiple Myeloma Care
Target the Future will provide education on progress in multiple myeloma, identify challenges in the community, and advance solutions to create a better future for patients and caregivers. Continue Reading
-
News
07 Dec 2021
AstraZeneca Unveils $1B Research Facility To Advance Gene-Editing
The Discovery Centre (DISC) in Cambridge, UK, will include advanced robotics, high-throughput screening, and AI-driven technology to advance gene-editing and cell therapies. Continue Reading
-
News
03 Dec 2021
Pfizer, AWS Collaborate To Improve Drug Development, Manufacturing
The collaboration will focus on supporting Pfizer in more rapidly and reliably advancing drug development and evaluating the potential health benefits for patients. Continue Reading
-
News
01 Dec 2021
Moderna Doses First Patients in Phase 2 Study of mRNA RSV Vaccine
Moderna’s mRNA RSV vaccine boosted neutralizing antibody titers against RSV-A nearly 14-fold and against RSV-B nearly 10-fold in a Phase 1 study. Continue Reading
-
News
30 Nov 2021
Pfizer Confirms COVID-19 Vaccine Safety, Efficacy in Adolescents
Pfizer and BioNTech’s COVID-19 vaccine is 100 percent effective in adolescents in a longer-term analysis, with no serious safety concerns identified. Continue Reading
-
News
22 Nov 2021
Moderna’s mRNA Therapeutic Helps Patients With Heart Failure
All patients treated with the mRNA therapeutic had NT-proBNP levels below heart failure limit at six months follow-up, compared to one of four patients who received a placebo. Continue Reading
-
News
17 Nov 2021
Opdivo Plus Chemotherapy Helps Non-Small Cell Lung Cancer Patients
Bristol Myers Squibb’s Opdivo plus chemotherapy improved event-free survival and pathologic complete response in non-small cell lung cancer patients. Continue Reading
-
News
16 Nov 2021
Jardiance Slows Kidney Decline by 40% in Heart Failure Patients
In the Phase 3 trial, Eli Lilly’s Jardiance was well tolerated, consistently improved cardiovascular outcomes, and reduced the risk of death or hospitalization across all heart failure patients. Continue Reading
-
News
11 Nov 2021
GSK’s Daprodustat Effective in Chronic Kidney Disease Patients
Two pivotal Phase 3 trials found that GSK’s drug improved or maintained chronic kidney disease patients within their target hemoglobin range. Continue Reading
-
News
11 Nov 2021
Moderna Enters Partnership To Advance Gene Editing Therapeutics
Moderna and Metagenomi will advance a series of in vivo gene editing therapeutics for patients with serious genetic conditions. Continue Reading
-
News
10 Nov 2021
Gilead, Merck Initiate Phase 2 Study for HIV Treatment in Adults
The Phase 2 study will evaluate the combination HIV treatment, islatravir and lenacapavir, in virologically suppressed individuals living with the disease across 25 sites in the US. Continue Reading
-
News
09 Nov 2021
Abbott Increases Clinical Trial Diversity In Medical Research
Abbott’s new initiative will increase clinical trial diversity in medical research, boosting insights into how different groups respond to new therapies. Continue Reading
-
News
09 Nov 2021
Pfizer’s COVID-19 Treatment Reduces Hospitalization by 89%
In the Phase 2/3 trial, 1% of patients who received Pfizer’s COVID-19 treatment, PAXLOVID, were hospitalized through Day 28, compared to 6.7% of patients in the placebo group. Continue Reading
-
News
04 Nov 2021
Moderna Doses the First Participant in Study of CMV mRNA Vaccine
The Phase 3 study of Moderna’s mRNA vaccine will evaluate the safety and efficacy of the vaccine against primary CMV infection in women ages 16 to 40 years from 150 sites globally. Continue Reading
-
News
03 Nov 2021
Roche Launches Genomic Profiling Kit to Boost Oncology Research
The genomic profile kit analyzes 324 genes across four main alterations known to cause and drive cancer, boosting oncology research and treatment options. Continue Reading
-
News
02 Nov 2021
Collaboration to Study Antibody Drug, Keytruda in Lung Cancer
Daiichi Sankyo, AstraZeneca, and Merck have entered into a second clinical trial collaboration to evaluate a TROP2 directed DXd antibody drug with Merck’s Keytruda in Lung cancer patients. Continue Reading
-
News
01 Nov 2021
Eli Lilly Drug Proves Effective In Adults With Type 2 Diabetes
About 91% of patients receiving the highest dose of Eli Lilly’s tirzepatide saw an A1C reduction of 2.58 percent, compared to 51% of those who received insulin glargine. Continue Reading
-
News
29 Oct 2021
NIH, FDA, 15 Orgs Boost Gene Therapy Development for Rare Diseases
The organizations will accelerate and streamline gene therapy development for rare diseases through the newly launched Bespoke Gene Therapy Consortium. Continue Reading
-
News
27 Oct 2021
Bristol Myers Squibb Reinforces Efficacy of MS Drug, Zeposia
The Phase 3 trial found 75% and 71% of patients receiving Bristol Myers Squibb’s MS drug at 36 and 48 months were relapse-free, respectively. Continue Reading
-
News
27 Oct 2021
FDA Approves Eli Lilly and Company’s Breast Cancer Treatment
FDA based its approval on a Phase 3 trial, which found that patients who received the breast cancer treatment showed significant improvement in invasive disease-free survival. Continue Reading
-
News
26 Oct 2021
Cerner Leverages Real-World Evidence to Advance Therapies
Cerner’s new operating unit, Cerner Enviza, clarifies data through real-world evidence to get therapies to patients more quickly at a lower cost. Continue Reading
-
News
26 Oct 2021
Two Doses of Moderna’s COVID-19 Vaccine Effective in Children
In the Phase 2/3 trial, two 50-microgram doses of Moderna’s COVID-19 vaccine elicited robust neutralizing antibody response and a favorable safety profile. Continue Reading